301 related articles for article (PubMed ID: 21274000)
1. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.
Coles SJ; Wang EC; Man S; Hills RK; Burnett AK; Tonks A; Darley RL
Leukemia; 2011 May; 25(5):792-9. PubMed ID: 21274000
[TBL] [Abstract][Full Text] [Related]
2. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Chretien AS; Devillier R; Granjeaud S; Cordier C; Demerle C; Salem N; Wlosik J; Orlanducci F; Gorvel L; Fattori S; Hospital MA; Pakradouni J; Gregori E; Paul M; Rochigneux P; Pagliardini T; Morey M; Fauriat C; Dulphy N; Toubert A; Luche H; Malissen M; Blaise D; Nunès JA; Vey N; Olive D
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050021
[TBL] [Abstract][Full Text] [Related]
3. [The Expression and Function of NK Cells in Patients with Acute Myeloid Leukemia].
Liu L; Chen X; Jin HM; Zhao SS; Zhu Y; Qian SX; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):49-55. PubMed ID: 35123603
[TBL] [Abstract][Full Text] [Related]
4. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
5. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
[TBL] [Abstract][Full Text] [Related]
6. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
[TBL] [Abstract][Full Text] [Related]
7. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.
Khaznadar Z; Boissel N; Agaugué S; Henry G; Cheok M; Vignon M; Geromin D; Cayuela JM; Castaigne S; Pautas C; Raffoux E; Lachuer J; Sigaux F; Preudhomme C; Dombret H; Dulphy N; Toubert A
J Immunol; 2015 Sep; 195(6):2580-90. PubMed ID: 26246143
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
[TBL] [Abstract][Full Text] [Related]
9. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
10. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
Ingram W; Chan L; Guven H; Darling D; Kordasti S; Hardwick N; Barber L; Mufti GJ; Farzaneh F
Br J Haematol; 2009 Jun; 145(6):749-60. PubMed ID: 19388935
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade.
Godal R; Bachanova V; Gleason M; McCullar V; Yun GH; Cooley S; Verneris MR; McGlave PB; Miller JS
Biol Blood Marrow Transplant; 2010 May; 16(5):612-21. PubMed ID: 20139023
[TBL] [Abstract][Full Text] [Related]
12. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
13. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.
Fauriat C; Just-Landi S; Mallet F; Arnoulet C; Sainty D; Olive D; Costello RT
Blood; 2007 Jan; 109(1):323-30. PubMed ID: 16940427
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.
Memarian A; Nourizadeh M; Masoumi F; Tabrizi M; Emami AH; Alimoghaddam K; Hadjati J; Mirahmadian M; Jeddi-Tehrani M
Tumour Biol; 2013 Feb; 34(1):531-42. PubMed ID: 23179394
[TBL] [Abstract][Full Text] [Related]
16. NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.
Braciak TA; Wildenhain S; Roskopf CC; Schubert IA; Fey GH; Jacob U; Hopfner KP; Oduncu FS
J Transl Med; 2013 Nov; 11():289. PubMed ID: 24237598
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse.
Khaznadar Z; Henry G; Setterblad N; Agaugue S; Raffoux E; Boissel N; Dombret H; Toubert A; Dulphy N
Eur J Immunol; 2014 Oct; 44(10):3068-80. PubMed ID: 25041786
[TBL] [Abstract][Full Text] [Related]
20. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
